Recent advances and future directions in targeting the secretory apparatus in multiple myeloma

British Journal of Haematology

Volumn 168, Issue 1, 2015, Pages 14-25

  Auner, Holger W ^a   Cenci, Simone ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Endoplasmic reticulum; Endoplasmic reticulum associated degradation; Multiple myeloma; Proteasome; Unfolded protein response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; BIM PROTEIN; BORTEZOMIB; CARFILZOMIB; CRYOPYRIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 34; IMMUNOGLOBULIN; INOSITOL REQUIRING ENZYME 1; LENALIDOMIDE; MESSENGER RNA; MKC 3946; NELFINAVIR; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN KINASE RNA LIKE ER KINASE; PROTEIN P97; SECRETORY PROTEIN; STF 083010; STRESS ACTIVATED PROTEIN KINASE 1; THALIDOMIDE; TOYOCAMYCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF1; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT;

AUTOPHAGY; CELL DEATH; CELL FUNCTION; CYTOKINE RELEASE; DEUBIQUITINATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; RNA TRANSLATION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; HOMEOSTASIS; METABOLISM; MOLECULARLY TARGETED THERAPY; SECRETORY PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION; HOMEOSTASIS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PLASMA CELLS; PROTEASOME INHIBITORS; PROTEOLYSIS; SECRETORY PATHWAY; UNFOLDED PROTEIN RESPONSE;

EID: 84915822465     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13172     Document Type: Review

References (126)

1. van Anken, E., Romijn, E.P., Maggioni, C., Mezghrani, A., Sitia, R., Braakman, I. & Heck, A.J. (2003) Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity, 18, 243-253.
2. Aronson, L.I. & Davies, F.E. (2012) DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica, 97, 1119-1130.
3. Auner, H.W., Beham-Schmid, C., Dillon, N. & Sabbattini, P. (2010) The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. Blood, 116, 3445-3455.
4. Auner, H.W., Moody, A.M., Ward, T.H., Kraus, M., Milan, E., May, P., Chaidos, A., Driessen, C., Cenci, S., Dazzi, F., Rahemtulla, A., Apperley, J.F., Karadimitris, A. & Dillon, N. (2013) Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS ONE, 8, e74415.
5. Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell, 92, 367-380.
6. Bertolotti, A., Zhang, Y., Hendershot, L.M., Harding, H.P. & Ron, D. (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature Cell Biology, 2, 326-332.
7. Bianchi, G. & Ghobrial, I.M. (2013) Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leukaemia & Lymphoma, 54, 229-241.
8. Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., Palladini, G., Giuliani, N., Anderson, K.C., Sitia, R. & Cenci, S. (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood, 113, 3040-3049.
9. Boyault, C., Gilquin, B., Zhang, Y., Rybin, V., Garman, E., Meyer-Klaucke, W., Matthias, P., Muller, C.W. & Khochbin, S. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO Journal, 25, 3357-3366.
10. Bringhen, S., Gay, F., Donato, F., Troia, R., Mina, R. & Palumbo, A. (2014) Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 23, 1193-1209.
11. Brioli, A., Giles, H., Pawlyn, C., Campbell, J.P., Kaiser, M.F., Melchor, L., Jackson, G.H., Gregory, W.M., Owen, R.G., Child, J.A., Davies, F.E., Cavo, M., Drayson, M.T. & Morgan, G.J. (2014) Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood, 123, 3414-3419.
12. de Bruin, G., Huber, E.M., Xin, B.T., van Rooden, E.J., Al-Ayed, K., Kim, K.B., Kisselev, A.F., Driessen, C., van der Stelt, M., van der Marel, G.A., Groll, M. & Overkleeft, H.S. (2014) Structure-based design of beta1i or beta5i specific inhibitors of human immunoproteasomes. Journal of Medicinal Chemistry, 57, 6197-6209.
13. Calfon, M., Zeng, H., Urano, F., Till, J.H., Hubbard, S.R., Harding, H.P., Clark, S.G. & Ron, D. (2002) IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature, 415, 92-96.
14. Carrasco, D.R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D.E., Zheng, M., Mani, M., Henderson, J., Pinkus, G.S., Munshi, N., Horner, J., Ivanova, E.V., Protopopov, A., Anderson, K.C., Tonon, G. & DePinho, R.A. (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell, 11, 349-360.
15. Cenci, S. (2012) The proteasome in terminal plasma cell differentiation. Seminars in Hematology, 49, 215-222.
16. Cenci, S., Mezghrani, A., Cascio, P., Bianchi, G., Cerruti, F., Fra, A., Lelouard, H., Masciarelli, S., Mattioli, L., Oliva, L., Orsi, A., Pasqualetto, E., Pierre, P., Ruffato, E., Tagliavacca, L. & Sitia, R. (2006) Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO Journal, 25, 1104-1113.
17. Cenci, S., van Anken, E. & Sitia, R. (2011) Proteostenosis and plasma cell pathophysiology. Current Opinion in Cell Biology, 23, 216-222.
18. Cenci, S., Oliva, L., Cerruti, F., Milan, E., Bianchi, G., Raule, M., Mezghrani, A., Pasqualetto, E., Sitia, R. & Cascio, P. (2012) Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. Journal of Leukocyte Biology, 92, 921-931.
19. Chaidos, A., Barnes, C.P., Cowan, G., May, P.C., Melo, V., Hatjiharissi, E., Papaioannou, M., Harrington, H., Doolittle, H., Terpos, E., Dimopoulos, M., Abdalla, S., Yarranton, H., Naresh, K., Foroni, L., Reid, A., Rahemtulla, A., Stumpf, M., Roberts, I. & Karadimitris, A. (2013) Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 121, 318-328.
20. Chauhan, D., Tian, Z., Nicholson, B., Kumar, K.G., Zhou, B., Carrasco, R., McDermott, J.L., Leach, C.A., Fulcinniti, M., Kodrasov, M.P., Weinstock, J., Kingsbury, W.D., Hideshima, T., Shah, P.K., Minvielle, S., Altun, M., Kessler, B.M., Orlowski, R., Richardson, P., Munshi, N. & Anderson, K.C. (2012) A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell, 22, 345-358.
21. Choi, A.M., Ryter, S.W. & Levine, B. (2013) Autophagy in human health and disease. New England Journal of Medicine, 368, 1845-1846.
22. Chou, T.F., Brown, S.J., Minond, D., Nordin, B.E., Li, K., Jones, A.C., Chase, P., Porubsky, P.R., Stoltz, B.M., Schoenen, F.J., Patricelli, M.P., Hodder, P., Rosen, H. & Deshaies, R.J. (2011) Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proceedings of the National Academy of Sciences of the United States of America, 108, 4834-4839.
23. Christianson, J.C. & Ye, Y. (2014) Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nature Structural & Molecular Biology, 21, 325-335.
24. Clarke, H.J., Chambers, J.E., Liniker, E. & Marciniak, S.J. (2014) Endoplasmic reticulum stress in malignancy. Cancer Cell, 25, 563-573.
25. Coux, O., Tanaka, K. & Goldberg, A.L. (1996) Structure and functions of the 20S and 26S proteasomes. Annual Review of Biochemistry, 65, 801-847.
26. Crawford, L.J. & Irvine, A.E. (2013) Targeting the ubiquitin proteasome system in haematological malignancies. Blood Reviews, 27, 297-304.
27. Dobson, C.M. (2004) Principles of protein folding, misfolding and aggregation. Seminars in Cell & Developmental Biology, 15, 3-16.
28. Fennell, D.A., Chacko, A. & Mutti, L. (2008) BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene, 27, 1189-1197.
29. Fortun, J., Dunn, W.A. Jr, Joy, S., Li, J. & Notterpek, L. (2003) Emerging role for autophagy in the removal of aggresomes in Schwann cells. Journal of Neuroscience, 23, 10672-10680.
30. Fritsch, R.M., Schneider, G., Saur, D., Scheibel, M. & Schmid, R.M. (2007) Translational repression of MCL-1 couples stress-induced eIF2 alpha phosphorylation to mitochondrial apoptosis initiation. Journal of Biological Chemistry, 282, 22551-22562.
31. Garcia-Manteiga, J.M., Mari, S., Godejohann, M., Spraul, M., Napoli, C., Cenci, S., Musco, G. & Sitia, R. (2011) Metabolomics of B to plasma cell differentiation. Journal of Proteome Research, 10, 4165-4176.
32. Glickman, M.H. & Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews, 82, 373-428.
33. Goldberg, A.L., Cascio, P., Saric, T. & Rock, K.L. (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Molecular Immunology, 39, 147-164.
34. Gotoh, T., Terada, K., Oyadomari, S. & Mori, M. (2004) hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death and Differentiation, 11, 390-402.
35. Groettrup, M., Kirk, C.J. & Basler, M. (2010) Proteasomes in immune cells: more than peptide producers? Nature Reviews Immunology, 10, 73-78.
36. Gunn, K.E., Gifford, N.M., Mori, K. & Brewer, J.W. (2004) A role for the unfolded protein response in optimizing antibody secretion. Molecular Immunology, 41, 919-927.
37. Han, J., Back, S.H., Hur, J., Lin, Y.H., Gildersleeve, R., Shan, J., Yuan, C.L., Krokowski, D., Wang, S., Hatzoglou, M., Kilberg, M.S., Sartor, M.A. & Kaufman, R.J. (2013) ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nature Cell Biology, 15, 481-490.
38. Hanna, J. & Finley, D. (2007) A proteasome for all occasions. FEBS Letters, 581, 2854-2861.
39. Harding, H.P., Zhang, Y., Bertolotti, A., Zeng, H. & Ron, D. (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Molecular Cell, 5, 897-904.
40. Hetz, C. (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nature Reviews Molecular Cell Biology, 13, 89-102.
41. Hibi, T. & Dosch, H.M. (1986) Limiting dilution analysis of the B cell compartment in human bone marrow. European Journal of Immunology, 16, 139-145.
42. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N.C., Mitsiades, N. & Anderson, K.C. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 1530-1534.
43. Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L. & Anderson, K.C. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 102, 8567-8572.
44. Hoang, B., Benavides, A., Shi, Y., Frost, P. & Lichtenstein, A. (2009) Effect of autophagy on multiple myeloma cell viability. Molecular Cancer Therapeutics, 8, 1974-1984.
45. Hu, J., Dang, N., Menu, E., De Bryune, E., Xu, D., Van Camp, B., Van Valckenborgh, E. & Vanderkerken, K. (2012) Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood, 119, 826-837.
46. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science, 327, 1345-1350.
47. Jiang, H.Y. & Wek, R.C. (2005) Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. Journal of Biological Chemistry, 280, 14189-14202.
48. Johnston, J.A., Ward, C.L. & Kopito, R.R. (1998) Aggresomes: a cellular response to misfolded proteins. Journal of Cell Biology, 143, 1883-1898.
49. Kaufman, J.L., Fabre, C., Lonial, S. & Richardson, P.G. (2013) Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clinical Lymphoma, Myeloma & Leukemia, 13, 370-376.
50. Kawabata, S., Gills, J.J., Mercado-Matos, J.R., Lopiccolo, J., Wilson, W. 3rd, Hollander, M.C. & Dennis, P.A. (2012) Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death & Disease, 3, e353.
51. Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A. & Yao, T.P. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115, 727-738.
52. Kawaguchi, T., Miyazawa, K., Moriya, S., Ohtomo, T., Che, X.F., Naito, M., Itoh, M. & Tomoda, A. (2011) Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. International Journal of Oncology, 38, 643-654.
53. Kincaid, E.Z., Che, J.W., York, I., Escobar, H., Reyes-Vargas, E., Delgado, J.C., Welsh, R.M., Karow, M.L., Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D. & Rock, K.L. (2012) Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nature Immunology, 13, 129-135.
54. Kirk, S.J., Cliff, J.M., Thomas, J.A. & Ward, T.H. (2010) Biogenesis of secretory organelles during B cell differentiation. Journal of Leukocyte Biology, 87, 245-255.
55. Kraus, M., Bader, J., Overkleeft, H. & Driessen, C. (2013) Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer Journal, 3, e103.
56. Kraus, M., Muller-Ide, H., Ruckrich, T., Bader, J., Overkleeft, H. & Driessen, C. (2014) Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leukemia Research, 38, 383-392.
57. Kronke, J., Udeshi, N.D., Narla, A., Grauman, P., Hurst, S.N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S.L., Carr, S.A. & Ebert, B.L. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science, 343, 301-305.
58. Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S. & Ichihara, A. (1990) Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 87, 7071-7075.
59. Lamy, L., Ngo, V.N., Emre, N.C., Shaffer, A.L. 3rd, Yang, Y., Tian, E., Nair, V., Kruhlak, M.J., Zingone, A., Landgren, O. & Staudt, L.M. (2013) Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell, 23, 435-449.
60. Lee, K., Tirasophon, W., Shen, X., Michalak, M., Prywes, R., Okada, T., Yoshida, H., Mori, K. & Kaufman, R.J. (2002) IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes & Development, 16, 452-466.
61. Lee, A.H., Iwakoshi, N.N., Anderson, K.C. & Glimcher, L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9946-9951.
62. Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J.J., Stewart, A.K., Reece, D.E., Chung, K.C. & Tiedemann, R.E. (2013) Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell, 24, 289-304.
63. Lichter, D.I., Danaee, H., Pickard, M.D., Tayber, O., Sintchak, M., Shi, H., Richardson, P.G., Cavenagh, J., Blade, J., Facon, T., Niesvizky, R., Alsina, M., Dalton, W., Sonneveld, P., Lonial, S., van de Velde, H., Ricci, D., Esseltine, D.L., Trepicchio, W.L., Mulligan, G. & Anderson, K.C. (2012) Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood, 120, 4513-4516.
64. Ling, S.C., Lau, E.K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P.J., Harrison, S., Fleming, S., Joshua, D.E. & Allen, J.D. (2012) Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica, 97, 64-72.
65. Lu, G., Middleton, R.E., Sun, H., Naniong, M., Ott, C.J., Mitsiades, C.S., Wong, K.K., Bradner, J.E. & Kaelin, W.G. Jr (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science, 343, 305-309.
66. Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136-1144.
67. Ma, Y., Shimizu, Y., Mann, M.J., Jin, Y. & Hendershot, L.M. (2010) Plasma cell differentiation initiates a limited ER stress response by specifically suppressing the PERK-dependent branch of the unfolded protein response. Cell Stress & Chaperones, 15, 281-293.
68. Magnaghi, P., D'Alessio, R., Valsasina, B., Avanzi, N., Rizzi, S., Asa, D., Gasparri, F., Cozzi, L., Cucchi, U., Orrenius, C., Polucci, P., Ballinari, D., Perrera, C., Leone, A., Cervi, G., Casale, E., Xiao, Y., Wong, C., Anderson, D.J., Galvani, A., Donati, D., O'Brien, T., Jackson, P.K. & Isacchi, A. (2013) Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nature Chemical Biology, 9, 548-556.
69. Malhotra, J.D. & Kaufman, R.J. (2007) The endoplasmic reticulum and the unfolded protein response. Seminars in Cell & Developmental Biology, 18, 716-731.
70. Marciniak, S.J., Yun, C.Y., Oyadomari, S., Novoa, I., Zhang, Y., Jungreis, R., Nagata, K., Harding, H.P. & Ron, D. (2004) CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes & Development, 18, 3066-3077.
71. McCullough, K.D., Martindale, J.L., Klotz, L.O., Aw, T.Y. & Holbrook, N.J. (2001) Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Molecular and Cellular Biology, 21, 1249-1259.
72. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H.M. & Voll, R.E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67, 1783-1792.
73. Meyer, H.H., Shorter, J.G., Seemann, J., Pappin, D. & Warren, G. (2000) A complex of mammalian ufd1 and npl4 links the AAA-ATPase, p97, to ubiquitin and nuclear transport pathways. EMBO Journal, 19, 2181-2192.
74. Michallet, A.S., Mondiere, P., Taillardet, M., Leverrier, Y., Genestier, L. & Defrance, T. (2011) Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS ONE, 6, e25820.
75. Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N.L., Malyankar, U.M., Hokenson, M., Pham, T., Zeng, Q., Patterson, J.B., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2012) Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood, 119, 5772-5781.
76. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377-2380.
77. Mizushima, N. & Komatsu, M. (2011) Autophagy: renovation of cells and tissues. Cell, 147, 728-741.
78. Moreau, P., Richardson, P.G., Cavo, M., Orlowski, R.Z., San Miguel, J.F., Palumbo, A. & Harousseau, J.L. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 120, 947-959.
79. Morgan, G.J., Walker, B.A. & Davies, F.E. (2012) The genetic architecture of multiple myeloma. Nature Reviews Cancer, 12, 335-348.
80. Mulligan, G., Lichter, D.I., Di Bacco, A., Blakemore, S.J., Berger, A., Koenig, E., Bernard, H., Trepicchio, W., Li, B., Neuwirth, R., Chattopadhyay, N., Bolen, J.B., Dorner, A.J., van de Velde, H., Ricci, D., Jagannath, S., Berenson, J.R., Richardson, P.G., Stadtmauer, E.A., Orlowski, R.Z., Lonial, S., Anderson, K.C., Sonneveld, P., San Miguel, J.F., Esseltine, D.L. & Schu, M. (2014) Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 123, 632-639.
81. Novoa, I., Zeng, H., Harding, H.P. & Ron, D. (2001) Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. Journal of Cell Biology, 153, 1011-1022.
82. Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, W.J. Jr, Lee, K.P. & Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907-4916.
83. Oerlemans, R., Franke, N.E., Assaraf, Y.G., Cloos, J., van Zantwijk, I., Berkers, C.R., Scheffer, G.L., Debipersad, K., Vojtekova, K., Lemos, C., van der Heijden, J.W., Ylstra, B., Peters, G.J., Kaspers, G.L., Dijkmans, B.A., Scheper, R.J. & Jansen, G. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 112, 2489-2499.
84. Orlowski, R.Z., Eswara, J.R., Lafond-Walker, A., Grever, M.R., Orlowski, M. & Dang, C.V. (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Research, 58, 4342-4348.
85. Oslowski, C.M., Hara, T., O'Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., Ishigaki, S., Zhu, L.J., Hayashi, E., Hui, S.T., Greiner, D., Kaufman, R.J., Bortell, R. & Urano, F. (2012) Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metabolism, 16, 265-273.
86. Papandreou, I., Denko, N.C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., Solow-Cordero, D.E., Bouley, D.M., Offner, F., Niwa, M. & Koong, A.C. (2011) Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood, 117, 1311-1314.
87. Pengo, N., Scolari, M., Oliva, L., Milan, E., Mainoldi, F., Raimondi, A., Fagioli, C., Merlini, A., Mariani, E., Pasqualetto, E., Orfanelli, U., Ponzoni, M., Sitia, R., Casola, S. & Cenci, S. (2013) Plasma cells require autophagy for sustainable immunoglobulin production. Nature Immunology, 14, 298-305.
88. Puthalakath, H., O'Reilly, L.A., Gunn, P., Lee, L., Kelly, P.N., Huntington, N.D., Hughes, P.D., Michalak, E.M., McKimm-Breschkin, J., Motoyama, N., Gotoh, T., Akira, S., Bouillet, P. & Strasser, A. (2007) ER stress triggers apoptosis by activating BH3-only protein Bim. Cell, 129, 1337-1349.
89. Radhakrishnan, S.K., Lee, C.S., Young, P., Beskow, A., Chan, J.Y. & Deshaies, R.J. (2010) Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Molecular Cell, 38, 17-28.
90. Radhakrishnan, S.K., den Besten, W. & Deshaies, R.J. (2014) p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife, 3, e01856.
91. Raule, M., Cerruti, F. & Cascio, P. (2014) Enhanced rate of degradation of basic proteins by 26S immunoproteasomes. Biochimica et Biophysica Acta, 1843, 1942-1947.
92. Reimold, A.M., Iwakoshi, N.N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., Gravallese, E.M., Friend, D., Grusby, M.J., Alt, F. & Glimcher, L.H. (2001) Plasma cell differentiation requires the transcription factor XBP-1. Nature, 412, 300-307.
93. Ri, M., Iida, S., Nakashima, T., Miyazaki, H., Mori, F., Ito, A., Inagaki, A., Kusumoto, S., Ishida, T., Komatsu, H., Shiotsu, Y. & Ueda, R. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia, 24, 1506-1512.
94. Ri, M., Tashiro, E., Oikawa, D., Shinjo, S., Tokuda, M., Yokouchi, Y., Narita, T., Masaki, A., Ito, A., Ding, J., Kusumoto, S., Ishida, T., Komatsu, H., Shiotsu, Y., Ueda, R., Iwawaki, T., Imoto, M. & Iida, S. (2012) Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer Journal, 2, e79.
95. Ruckrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., Overkleeft, H.S., Kalbacher, H. & Driessen, C. (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia, 23, 1098-1105.
96. Rutkowski, D.T., Arnold, S.M., Miller, C.N., Wu, J., Li, J., Gunnison, K.M., Mori, K., Sadighi Akha, A.A., Raden, D. & Kaufman, R.J. (2006) Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biology, 4, e374.
97. Santo, L., Hideshima, T., Kung, A.L., Tseng, J.C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J.H., Mazitschek, R., Ogier, W.C., Cirstea, D., Rodig, S., Eda, H., Scullen, T., Canavese, M., Bradner, J., Anderson, K.C., Jones, S.S. & Raje, N. (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 119, 2579-2589.
98. Sha, Z. & Goldberg, A.L. (2014) Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97. Current Biology, 24, 1573-1583.
99. Shaffer, A.L., Shapiro-Shelef, M., Iwakoshi, N.N., Lee, A.H., Qian, S.B., Zhao, H., Yu, X., Yang, L., Tan, B.K., Rosenwald, A., Hurt, E.M., Petroulakis, E., Sonenberg, N., Yewdell, J.W., Calame, K., Glimcher, L.H. & Staudt, L.M. (2004) XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity, 21, 81-93.
100. Shaughnessy, J.D. Jr, Qu, P., Usmani, S., Heuck, C.J., Zhang, Q., Zhou, Y., Tian, E., Hanamura, I., van Rhee, F., Anaissie, E., Epstein, J., Nair, B., Stephens, O., Williams, R., Waheed, S., Alsayed, Y., Crowley, J. & Barlogie, B. (2011) Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood, 118, 3512-3524.
101. Smith, K.G., Hewitson, T.D., Nossal, G.J. & Tarlinton, D.M. (1996) The phenotype and fate of the antibody-forming cells of the splenic foci. European Journal of Immunology, 26, 444-448.
102. Steffen, J., Seeger, M., Koch, A. & Kruger, E. (2010) Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Molecular Cell, 40, 147-158.
103. Suraweera, A., Munch, C., Hanssum, A. & Bertolotti, A. (2012) Failure of amino acid homeostasis causes cell death following proteasome inhibition. Molecular Cell, 48, 242-253.
104. Tabas, I. & Ron, D. (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nature Cell Biology, 13, 184-190.
105. Taubenheim, N., Tarlinton, D.M., Crawford, S., Corcoran, L.M., Hodgkin, P.D. & Nutt, S.L. (2012) High rate of antibody secretion is not integral to plasma cell differentiation as revealed by XBP-1 deficiency. Journal of Immunology, 189, 3328-3338.
106. Taylor, J.P., Tanaka, F., Robitschek, J., Sandoval, C.M., Taye, A., Markovic-Plese, S. & Fischbeck, K.H. (2003) Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Human Molecular Genetics, 12, 749-757.
107. Timmins, J.M., Ozcan, L., Seimon, T.A., Li, G., Malagelada, C., Backs, J., Backs, T., Bassel-Duby, R., Olson, E.N., Anderson, M.E. & Tabas, I. (2009) Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. The Journal of Clinical Investigation, 119, 2925-2941.
108. Travers, K.J., Patil, C.K., Wodicka, L., Lockhart, D.J., Weissman, J.S. & Walter, P. (2000) Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell, 101, 249-258.
109. Tsai, Y.C. & Weissman, A.M. (2011) Ubiquitylation in ERAD: reversing to go forward? PLoS Biology, 9, e1001038.
110. Tsujimoto, Y., Tomita, Y., Hoshida, Y., Kono, T., Oka, T., Yamamoto, S., Nonomura, N., Okuyama, A. & Aozasa, K. (2004) Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clinical Cancer Research, 10, 3007-3012.
111. Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H.P. & Ron, D. (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science, 287, 664-666.
112. Valle, C.W., Min, T., Bodas, M., Mazur, S., Begum, S., Tang, D. & Vij, N. (2011) Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS ONE, 6, e29073.
113. Vembar, S.S. & Brodsky, J.L. (2008) One step at a time: endoplasmic reticulum-associated degradation. Nature Reviews Molecular Cell Biology, 9, 944-957.
114. Voges, D., Zwickl, P. & Baumeister, W. (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annual Review of Biochemistry, 68, 1015-1068.
115. Vogl, D.T., Stadtmauer, E.A., Tan, K.S., Heitjan, D.F., Davis, L.E., Pontiggia, L., Rangwala, R., Piao, S., Chang, Y.C., Scott, E.C., Paul, T.M., Nichols, C.W., Porter, D.L., Kaplan, J., Mallon, G., Bradner, J.E. & Amaravadi, R.K. (2014) Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy, 10, 1380-1390.
116. Walter, P. & Ron, D. (2011) The unfolded protein response: from stress pathway to homeostatic regulation. Science, 334, 1081-1086.
117. Wang, Q., Mora-Jensen, H., Weniger, M.A., Perez-Galan, P., Wolford, C., Hai, T., Ron, D., Chen, W., Trenkle, W., Wiestner, A. & Ye, Y. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 2200-2205.
118. Weathington, N.M. & Mallampalli, R.K. (2014) Emerging therapies targeting the ubiquitin proteasome system in cancer. The Journal of Clinical Investigation, 124, 6-12.
119. Wiertz, E.J., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T.R., Rapoport, T.A. & Ploegh, H.L. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature, 384, 432-438.
120. Wojcik, C., Yano, M. & DeMartino, G.N. (2004) RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. Journal of Cell Science, 117, 281-292.
121. Yamamoto, S., Tomita, Y., Uruno, T., Hoshida, Y., Qiu, Y., Iizuka, N., Nakamichi, I., Miyauchi, A. & Aozasa, K. (2005) Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer. Annals of Surgical Oncology, 12, 925-934.
122. Ye, J., Rawson, R.B., Komuro, R., Chen, X., Dave, U.P., Prywes, R., Brown, M.S. & Goldstein, J.L. (2000) ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Molecular Cell, 6, 1355-1364.
123. Ye, Y., Meyer, H.H. & Rapoport, T.A. (2001) The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature, 414, 652-656.
124. Ye, Y., Shibata, Y., Kikkert, M., van Voorden, S., Wiertz, E. & Rapoport, T.A. (2005) Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proceedings of the National Academy of Sciences of the United States of America, 102, 14132-14138.
125. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T. & Mori, K. (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell, 107, 881-891.
126. Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.